Compare TEX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | RYTM |
|---|---|---|
| Founded | 1933 | 2008 |
| Country | United States | United States |
| Employees | N/A | 414 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.3B |
| IPO Year | 1994 | 2017 |
| Metric | TEX | RYTM |
|---|---|---|
| Price | $51.06 | $89.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 18 |
| Target Price | $78.17 | ★ $138.88 |
| AVG Volume (30 Days) | ★ 1.3M | 749.2K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $5,421,000,000.00 | N/A |
| Revenue This Year | $50.27 | $66.04 |
| Revenue Next Year | $7.44 | $79.38 |
| P/E Ratio | $252.65 | ★ N/A |
| Revenue Growth | ★ 5.73 | N/A |
| 52 Week Low | $41.70 | $74.50 |
| 52 Week High | $74.69 | $122.20 |
| Indicator | TEX | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 32.40 | 29.52 |
| Support Level | N/A | $82.43 |
| Resistance Level | $62.24 | $92.51 |
| Average True Range (ATR) | 2.10 | 3.45 |
| MACD | -0.29 | -0.32 |
| Stochastic Oscillator | 12.61 | 21.98 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.